Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May;58(2-3):300-6.
doi: 10.1007/s12026-014-8507-2.

A killer choice for cancer immunotherapy

Affiliations
Review

A killer choice for cancer immunotherapy

Tobi L Schmidt et al. Immunol Res. 2014 May.

Abstract

The promise of cell-based immunotherapies for the treatment of cancer offers the potential of therapeutic synergy with chemo- and radiotherapies that may overcome current limitations leading to durable responses and prevention of recurrence. There is a wide array of cell-based immunotherapies that are either poised to enter cancer clinical trials or are in clinical trials, and many are showing some success. Yet within this field, there are clear obstacles that need to be overcome, including limited access across tissue barriers, development of antigen tolerance, and the immunosuppressive microenvironment of tumors. Through an understanding of immune cell signaling and trafficking, immune cell populations can be selected for adoptive transfer, and delivery strategies can be developed that circumvent these obstacles to effectively direct populations of cells with robust anti-tumor efficacy to the target. Within the realm of immune cell therapies, cytokine-induced killer (CIK) cells have demonstrated promising trafficking patterns, effective delivery of synergistic therapeutics, and stand-alone efficacy. Here, we discuss the next generation of CIK therapies and their application for the effective treatment of a wide variety of cancers.

PubMed Disclaimer

Similar articles

Cited by

References

    1. PLoS One. 2013 Nov 13;8(11):e78980 - PubMed
    1. Int Immunopharmacol. 2007 Dec 15;7(13):1802-7 - PubMed
    1. Br J Cancer. 1999 Nov;81(6):1009-16 - PubMed
    1. Blood. 1993 Mar 1;81(5):1333-41 - PubMed
    1. Int Immunopharmacol. 2007 Dec 15;7(13):1793-801 - PubMed

LinkOut - more resources